149 related articles for article (PubMed ID: 28898983)
1. Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.
Khoury T; Zirpoli G; Cohen SM; Geradts J; Omilian A; Davis W; Bshara W; Miller R; Mathews MM; Troester M; Palmer JR; Ambrosone CB
Am J Clin Pathol; 2017 Aug; 148(2):108-118. PubMed ID: 28898983
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
[TBL] [Abstract][Full Text] [Related]
3. Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.
Muftah AA; Aleskandarany MA; Al-Kaabi MM; Sonbul SN; Diez-Rodriguez M; Nolan CC; Caldas C; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2017 Jul; 164(2):341-348. PubMed ID: 28478613
[TBL] [Abstract][Full Text] [Related]
4. Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer.
Tramm T; Kyndi M; Sørensen FB; Overgaard J; Alsner J
Acta Oncol; 2018 Jan; 57(1):102-106. PubMed ID: 29202620
[TBL] [Abstract][Full Text] [Related]
5. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer.
Besusparis J; Plancoulaine B; Rasmusson A; Augulis R; Green AR; Ellis IO; Laurinaviciene A; Herlin P; Laurinavicius A
Diagn Pathol; 2016 Aug; 11(1):82. PubMed ID: 27576949
[TBL] [Abstract][Full Text] [Related]
6. Soy consumption and histopathologic markers in breast tissue using tissue microarrays.
Maskarinec G; Erber E; Verheus M; Hernandez BY; Killeen J; Cashin S; Cline JM
Nutr Cancer; 2009; 61(5):708-16. PubMed ID: 19838945
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
[TBL] [Abstract][Full Text] [Related]
8. Tissue microarray sampling strategy for prostate cancer biomarker analysis.
Rubin MA; Dunn R; Strawderman M; Pienta KJ
Am J Surg Pathol; 2002 Mar; 26(3):312-9. PubMed ID: 11859202
[TBL] [Abstract][Full Text] [Related]
9. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
10. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma.
Drev P; Grazio SF; Bracko M
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):179-84. PubMed ID: 18227723
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
12. Tissue microarrays: one size does not fit all.
Eckel-Passow JE; Lohse CM; Sheinin Y; Crispen PL; Krco CJ; Kwon ED
Diagn Pathol; 2010 Jul; 5():48. PubMed ID: 20609235
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays.
Su Y; Shrubsole MJ; Ness RM; Cai Q; Kataoka N; Washington K; Zheng W
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1719-26. PubMed ID: 16985035
[TBL] [Abstract][Full Text] [Related]
14. Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer.
Holm J; Yu NY; Johansson A; Ploner A; Hall P; Lindström LS; Czene K
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442660
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of ki-67 in breast carcinoma: tissue microarray method versus whole section analysis- potentials and pitfalls.
Dedić Plavetić N; Jakić-Razumović J; Kulić A; Sirotković-Skerlev M; Barić M; Vrbanec D
Pathol Oncol Res; 2015 Apr; 21(2):315-24. PubMed ID: 25096394
[TBL] [Abstract][Full Text] [Related]
16. Validation of tissue microarray technology in malignant peripheral nerve sheath tumours.
Cunha KS; Caruso AC; Gonçalves AS; Bernardo VG; Pires AR; da Fonseca EC; de Faria PA; da Silva LE; Geller M; de Moura-Neto RS; Lopes VS
J Clin Pathol; 2009 Jul; 62(7):629-33. PubMed ID: 19318344
[TBL] [Abstract][Full Text] [Related]
17. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.
Dekker TJ; Borg ST; Hooijer GK; Meijer SL; Wesseling J; Boers JE; Schuuring E; Bart J; van Gorp J; Mesker WE; Kroep JR; Smit VT; van de Vijver MJ
Breast Cancer Res; 2012 Jun; 14(3):R93. PubMed ID: 22694844
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer subtypes and the risk of local and regional relapse.
Voduc KD; Cheang MC; Tyldesley S; Gelmon K; Nielsen TO; Kennecke H
J Clin Oncol; 2010 Apr; 28(10):1684-91. PubMed ID: 20194857
[TBL] [Abstract][Full Text] [Related]
19. Larger core size has superior technical and analytical accuracy in bladder tissue microarray.
Eskaros AR; Egloff SA; Boyd KL; Richardson JE; Hyndman ME; Zijlstra A
Lab Invest; 2017 Mar; 97(3):335-342. PubMed ID: 28112755
[TBL] [Abstract][Full Text] [Related]
20. Concordance between tissue microarray and whole-section estrogen receptor expression and intratumoral heterogeneity.
Gulbahce HE; Gamez R; Dvorak L; Forster C; Varghese L
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):340-3. PubMed ID: 22495371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
